Le Lézard
Classified in: Health
Subject: ATY

POMERANTZ LLP and GLANCY PRONGAY & MURRAY LLP announce proposed class action settlement for persons or entities who purchased or otherwise acquired the common stock of Unilife Corporation between November 9, 2011 and November 14, 2016


NEW YORK, Oct. 20, 2017 /PRNewswire/ --

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK

 

In re UNILIFE CORPORATION
SECURITIES LITIGATION

 

Master File No. 16-cv-03976-RA

Honorable Ronnie Abrams

SUMMARY NOTICE OF (I) PENDENCY OF CLASS ACTION AND PROPOSED SETTLEMENT; (II) SETTLEMENT FAIRNESS HEARING; AND (III) MOTION FOR AN AWARD OF ATTORNEYS' FEES AND REIMBURSEMENT OF LITIGATION EXPENSES

TO:  All persons and entities who, during the period between November 9, 2011 and November 14, 2016 inclusive, purchased or otherwise acquired the common stock of Unilife Corporation ("Unilife") and were damaged thereby (the "Settlement Class"):

PLEASE READ THIS NOTICE CAREFULLY, YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.

YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the Southern District of New York, that the above-captioned litigation (the "Action") has been certified as a class action on behalf of the Settlement Class, except for certain persons and entities who are excluded from the Settlement Class by definition as set forth in the full printed Notice of (I) Pendency of Class Action and Proposed Settlement; (II) Settlement Fairness Hearing; and (III) Motion for an Award of Attorneys' Fees and Reimbursement of Litigation Expenses (the "Notice").

YOU ARE ALSO NOTIFIED that Plaintiffs in the Action have reached a proposed settlement of the Action for $4,400,000 in cash (the "Settlement"), that, if approved, will resolve all claims in the Action.

A hearing will be held on January 25, 2018 at 9:00 a.m., before the Honorable Ronnie Abrams at the United States District Court for the Southern District of New York, Thurgood Marshall United States Courthouse, Courtroom 1506, 40 Foley Square, New York, NY 10007, to determine (i) whether the proposed Settlement should be approved as fair, reasonable, and adequate; (ii) whether the Action should be dismissed with prejudice against Defendants, and the Releases specified and described in the Stipulation and Agreement of Settlement dated March 22, 2017 (and in the Notice) should be granted; (iii) whether the proposed Plan of Allocation should be approved as fair and reasonable; and (iv) whether Lead Counsel's application for an award of attorneys' fees and reimbursement of expenses should be approved.

If you are a member of the Settlement Class, your rights will be affected by the pending Action and the Settlement, and you may be entitled to share in the Settlement Fund.  If you have not yet received the Notice and Claim Form, you may obtain copies of these documents by contacting the Claims Administrator at In re Unilife Corporation Securities Litigation, c/o JND Legal Administration, P.O. Box 6847, Broomfield, CO 80021, 1-844-864-9035.  Copies of the Notice and Claim Form can also be downloaded from the website maintained by the Claims Administrator, www.unilifesecuritieslitigation.com

If you are a member of the Settlement Class, in order to be eligible to receive a payment under the proposed Settlement, you must submit a Claim Form postmarked no later than February 20, 2018.  If you are a Settlement Class Member and do not submit a proper Claim Form, you will not be eligible to share in the distribution of the net proceeds of the Settlement but you will nevertheless be bound by any judgments or orders entered by the Court in the Action.

If you are a member of the Settlement Class and wish to exclude yourself from the Settlement Class, you must submit a request for exclusion such that it is received no later than January 4, 2018, in accordance with the instructions set forth in the Notice.  If you properly exclude yourself from the Settlement Class, you will not be bound by any judgments or orders entered by the Court in the Action and you will not be eligible to share in the proceeds of the Settlement. 

Any objections to the proposed Settlement, the proposed Plan of Allocation, or Lead Counsel's motion for attorneys' fees and reimbursement of expenses, must be filed with the Court and delivered to Lead Counsel and Defendants' Counsel such that they are received no later than January 4, 2018, in accordance with the instructions set forth in the Notice.

Please do not contact the Court, the Clerk's office, Unilife, or its counsel regarding this notice.  All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to Lead Counsel or the Claims Administrator.

Inquiries, other than requests for the Notice and Claim Form, should be made to Lead Counsel:

POMERANTZ LLP

GLANCY PRONGAY & MURRAY LLP

Jeremy Lieberman, Esq.

Lionel Z. Glancy, Esq.

600 Third Ave., 20th Floor

1925 Century Park East, Suite 2100

New York, NY  10016

Los Angeles, CA 90067

1-888-476-6529

1-888-773-9224

[email protected]

[email protected]

Requests for the Notice and Claim Form should be made to:

In re Unilife Corporation Securities Litigation
c/o JND Legal Administration
P.O. Box 6847
Broomfield, CO 80021
1-844-864-9035
www.unilifesecuritieslitigation.com

By Order of the Court

 

SOURCE POMERANTZ LLP


These press releases may also interest you

at 07:05
At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays. Simplifying...

at 07:00
Bristol Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) in combination with cisplatin and gemcitabine for the...

at 07:00
R&D Leader and software architect with more than three decades of experience designing, developing,...

at 07:00
Gordian Biotechnology, an in vivo drug discovery and development...

at 07:00
GeBBS Healthcare Solutions, Inc.(ChrysCapital portfolio company) a leading provider of technology enabled Revenue Cycle Management (RCM) & Risk Adjustment Solutions for Healthcare Providers and Payers, announced the acquisition of CCD Health, a...

at 07:00
Many American children...



News published on and distributed by: